Replies to post #81284 on Biotech Values

[mcbio]

Re: MEDX

MEDX is a good company and I'm surprised they weren't bought out much earlier. I had the stock on my watchlist for some time and have always liked it but can honestly, and unfortunately, say that I was never close to investing as there was always another company I was even more interested in. My ultimate intention was to take a real close look if ipilimumab failed in Phase 3 and the stock tanked given the breadth of their pipeline.

[croumagnon]

I am elated about the MEDX buyout since I am loaded on call options at $10, $11, and $12 on the basis that I considered it a prime takeover candidate for some time. However, I am surprised it did not fetch a much higher premium as in the $20s...

BMY-MEDX deal: With a 90% premium, all-cash terms, a no shop clause, and no need for financing, this deal is a fait accompli.

Perhaps but I think many shareholders may feel the same way I do and it is possible that the deal may be rejected by shareholders until BMY, or someone else, gives a higher offer. In view of that, I am wondering whether I should unload my call options tomorrow or hold on for a possible higher price...

[DewDiligence]

Survey: Which Acquiring Company Got the Best Deal?

a) AMGN buy of Abgenix for $2.4B (2005)
b) AZN buy of Cambridge Antibody Technology for $1.3B (2006)
c) BMY buy of MEDX for $2.1B (2009)

Note: the buyout amounts above are adjusted for the acquired company’s net cash/net debt.

To vote, please go to
http://investorshub.advfn.com/boards/board_surveymenu.asp?board_id=1418
and select survey #127.